Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study
Status:
Completed
Trial end date:
2018-02-27
Target enrollment:
Participant gender:
Summary
This was a randomized, double-blind trial to evaluate deferasirox vs placebo in patients with
myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload .The trial was
conducted in 17 countries, started in 2010 and ended in 2018.